ZURA

Zura Bio Ltd ZURA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-26.30M

Quarter to Jun 30

Free cash flow

$18.87M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$428.85M total
SUVRETTA CAPITAL MANAGEMENT, LLC
$55.71M+4.1%
VR Adviser, LLC
$37.97M0.0%
MPM BioImpact LLC
$26.39MNew
GREAT POINT PARTNERS LLC
$24.87M0.0%
JPMORGAN CHASE & CO
$24.52M-2.3%
BRAIDWELL LP
$23.48M-0.2%
Siren, L.L.C.
$22.04M0.0%
BlackRock, Inc.
$21.33M+690.3%
Commodore Capital LP
$19.18M0.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$16.23M0.0%
Saturn V Capital Management LP
$12.40M+184.0%
QVT Financial LP
$11.18M+44.6%
ADAR1 Capital Management, LLC
$10.38M+179.1%
ARMISTICE CAPITAL, LLC
$9.65M+8.6%
GEODE CAPITAL MANAGEMENT, LLC
$9.35M+200.2%
Affinity Asset Advisors, LLC
$8.64M-42.9%
StemPoint Capital LP
$8.07M+81.6%
Ikarian Capital, LLC
$7.19M+2.1%
EcoR1 Capital, LLC
$6.96M0.0%
Vestal Point Capital, LP
$6.93M+129.7%
STATE STREET CORP
$5.91M+413.8%
Boxer Capital Management, LLC
$5.31M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$4.41M+53.5%
GOLDMAN SACHS GROUP INC
$3.39M+275.3%
FMR LLC
$3.12M-0.2%
See all 95 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ZURA

Earnings Per Share

13fpro.ai/company/ZURA

Loading ratio trend…

ZURA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Zura Bio Ltd (ZURA): stock profile, AI score and financials

Zura Bio Ltd (ZURA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ZURA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Zura Bio Ltd reports net income of $-26.3M, free cash flow of $18.9M. ZURA trades on the Nasdaq exchange and files with the SEC under CIK 1855644. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zura Bio Ltd directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1855644 →